Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ibnsina Pharma's Total Liabilities for the quarter that ended in Mar. 2026 was E£36,285 Mil.
Ibnsina Pharma's quarterly Total Liabilities
increased
from Sep. 2025 (E£33,176.15 Mil) to Dec. 2025 (E£33,429.68 Mil) and
increased
from Dec. 2025 (E£33,429.68 Mil) to Mar. 2026 (E£36,284.84 Mil).
Ibnsina Pharma's annual Total Liabilities
increased
from Dec. 2023 (E£17,100.69 Mil) to Dec. 2024 (E£26,610.34 Mil) and
increased
from Dec. 2024 (E£26,610.34 Mil) to Dec. 2025 (E£33,429.68 Mil).
Ibnsina Pharma Total Liabilities Related Terms
Ibnsina Pharma Total Liabilities Historical Data
* Premium members only.
The historical data trend for Ibnsina Pharma's Total Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
Ibnsina Pharma's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Total Liabilities of E£36,285 Mil mean?
Ibnsina Pharma (CAI:ISPH) has a Total Liabilities of E£36,285 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Ibnsina Pharma and its competitors.
Is Ibnsina Pharma's Total Liabilities too high?
Ibnsina Pharma's current Total Liabilities is E£36,285 Mil. Overall, Ibnsina Pharma has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ibnsina Pharma's Total Liabilities compare to MCK and CAH?
Ibnsina Pharma's Total Liabilities of E£36,285 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Distribution company?
A good Total Liabilities depends on the Medical Distribution industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Ibnsina Pharma and its competitors. Ibnsina Pharma's current Total Liabilities is E£36,285 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ibnsina Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ibnsina Pharma (CAI:ISPH) is currently considered Modestly Overvalued. The stock's GF Value™ is E£10.56, compared to a current price of E£11.73 — trading 11.1% above its estimated fair value. The current Total Liabilities is E£36,285 Mil. Ibnsina Pharma's overall GF Score™ is 86/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Ibnsina Pharma (CAI:ISPH), the current Total Liabilities is E£36,285 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ibnsina Pharma (CAI:ISPH) Overvalued in 2026?
Based on GuruFocus' analysis, Ibnsina Pharma stock appears to be overvalued.
The current stock price of E£11.73 is trading 11.1% above its estimated GF Value™ of E£10.56.
GuruFocus considers Ibnsina Pharma to be Modestly Overvalued.
Key valuation signals for CAI:ISPH:
Total Liabilities: E£36,285 Mil
GF Value™: E£10.56 vs. price of E£11.73 (11.1% above fair value)
No single metric tells the full story. See the CAI:ISPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ibnsina Pharma is an Egypt-based pharmaceutical distribution company. It is engaged in purchasing and selling in wholesale and distribution of pharmaceutical, semi- pharmaceutical, and cosmetic products. It distributes a portfolio of pharmaceutical products from local and multinational pharmaceutical companies to retail pharmacies, wholesalers, hospitals, and public health institutions. In addition, the company also offers services including warehousing and logistics, marketing solutions, importation, packaging, market research, and analysis.
86GF Score
Get the complete analysis for CAI:ISPH
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:ISPH has been successfully added to your 
